TheStreet downgraded shares of Misonix (NASDAQ:MSON) from a c- rating to a d rating in a report published on Thursday, June 20th, TheStreetRatingsTable reports.
Separately, BTIG Research assumed coverage on Misonix in a report on Wednesday, June 12th. They set a buy rating and a $29.00 price target for the company. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $27.00.
Shares of MSON stock traded down $2.04 during mid-day trading on Thursday, hitting $23.81. The company’s stock had a trading volume of 125,049 shares, compared to its average volume of 94,604. Misonix has a 52-week low of $12.91 and a 52-week high of $27.54. The company has a 50-day moving average of $24.32.
A number of large investors have recently made changes to their positions in MSON. Vanguard Group Inc. grew its stake in Misonix by 15.7% in the third quarter. Vanguard Group Inc. now owns 213,040 shares of the medical equipment provider’s stock worth $3,941,000 after purchasing an additional 28,889 shares in the last quarter. Tibra Equities Europe Ltd bought a new position in Misonix in the first quarter worth approximately $327,000. Acadian Asset Management LLC grew its stake in Misonix by 95.3% in the first quarter. Acadian Asset Management LLC now owns 18,558 shares of the medical equipment provider’s stock worth $357,000 after purchasing an additional 9,054 shares in the last quarter. Geode Capital Management LLC grew its stake in Misonix by 5.3% in the fourth quarter. Geode Capital Management LLC now owns 35,095 shares of the medical equipment provider’s stock worth $561,000 after purchasing an additional 1,775 shares in the last quarter. Finally, Rathbone Brothers plc boosted its position in Misonix by 6.2% during the 1st quarter. Rathbone Brothers plc now owns 15,500 shares of the medical equipment provider’s stock valued at $298,000 after acquiring an additional 900 shares in the last quarter. 21.17% of the stock is currently owned by institutional investors.
Misonix Company Profile
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Read More: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.